KRAS and ovarian cancer: Alterations that were significantly enriched included APC, KRAS, and SMAD4 in patients with colorectal cancer (CRC); TP53 and CCNE1 in patients with ovarian cancer; PIK3CA and ESR1 mutations in patients with breast cancer; and CDK4 mutations in patients with sarcoma.